UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

Annals of oncology, 2020-07, Vol.31 (7), p.961-964

2020

Volltextzugriff (PDF)

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Annals of oncology, 2016-04, Vol.27 (4), p.559-574

2016

Volltextzugriff (PDF)

Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?

European journal of cancer (1990), 2019-11, Vol.122, p.72-90

2019

Volltextzugriff (PDF)

Quinolones in 2005: an update

Clinical microbiology and infection, 2005-04, Vol.11 (4), p.256-280

2005

Volltextzugriff (PDF)

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

Annals of oncology, 2017-11, Vol.28 (11), p.2860-2865

2017

Volltextzugriff (PDF)

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors

Annals of oncology, 2018-02, Vol.29 (2), p.518-520

2018

Volltextzugriff (PDF)

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study

Leukemia & lymphoma, 2024-06, Vol.65 (6), p.789-799

2024

Volltextzugriff (PDF)

Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency

QJM : An International Journal of Medicine, 2013-11, Vol.106 (11), p.1017-1022

2013

Volltextzugriff (PDF)

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Annals of oncology, 2021-11, Vol.32 (11), p.1445-1447

2021

Volltextzugriff (PDF)

Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients

Cancer chemotherapy and pharmacology, 2023-09, Vol.92 (3), p.229-233

2023

Volltextzugriff (PDF)

Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases

Cancer radiothérapie, 2023-09, Vol.27 (5), p.370-375

2023

Volltextzugriff (PDF)

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

European journal of cancer (1990), 2016-02, Vol.54, p.139-148

2016

Volltextzugriff (PDF)

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours

European journal of cancer (1990), 2018-05, Vol.95, p.68-74

2018

Volltextzugriff (PDF)

Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1

Annals of oncology, 2018-10, Vol.29, p.viii405-viii405

2018

Volltextzugriff (PDF)

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Annals of oncology, 2019-02, Vol.30 Suppl 1, p.i5

2019

Volltextzugriff (PDF)

Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events

Annals of oncology, 2018-10, Vol.29, p.viii427-viii428

2018

Volltextzugriff (PDF)

Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review

Annals of oncology, 2022-02, Vol.33 (2), p.158-168

2022

Volltextzugriff (PDF)

Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial

Annals of oncology, 2018-10, Vol.29, p.viii653-viii654

2018

Volltextzugriff (PDF)

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment

Clinical microbiology and infection, 2018-03, Vol.24 (3), p.216-218

2018

Volltextzugriff (PDF)

PB2102: PHASE 2 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL

HemaSphere, 2022-06, Vol.6 (Suppl), p.1973-1974

2022

Volltextzugriff (PDF)

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy

European journal of cancer (1990), 2017-04, Vol.75, p.308-309

2017

Volltextzugriff (PDF)

Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis

European journal of cancer (1990), 2023-08, Vol.189, p.112928-112928, Article 112928

2023

Volltextzugriff (PDF)

Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy

Annals of oncology, 2018-10, Vol.29, p.viii428-viii429

2018

Volltextzugriff (PDF)

Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial

Annals of oncology, 2018-10, Vol.29, p.viii378-viii379

2018

Volltextzugriff (PDF)

Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials

Annals of oncology, 2018-10, Vol.29, p.viii419-viii419

2018

Volltextzugriff (PDF)

1 – 25 von 256

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(226)
Mit Volltextzugriff
(218)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?

Quinolones in 2005: an update

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study

Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients

Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours

Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events

Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review

Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment

PB2102: PHASE 2 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy

Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis

Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy

Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial

Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials

Suchergebnisse filtern